Experimental combo therapy targets Hard-to-Treat pancreatic cancer

NCT ID NCT06205849

Recruiting now Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether injecting an immune-boosting drug (mitazalimab) directly into the tumor during a special electrical ablation procedure (IRE) is safe for people with locally advanced pancreatic cancer. The goal is to see if this approach can strengthen the body's immune response against the cancer and lower the chance of it coming back. The study involves 18 participants and focuses on safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mitazalimab (a CD40 antibody) injected into the tumor during irreversible electroporation (IRE) surgery
What this could lead to: If it works, this could point toward a new way to treat locally advanced pancreatic cancer by combining a targeted immune therapy with a tumor-destroying procedure.
What could go wrong: This is a very early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet proven. There is a risk of serious side effects from the drug or procedure, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

UCSD Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.